{"id":"application-of-t-lymphocytes","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"T-lymphocytes are a type of immune cell that play a crucial role in the body's defense against infection and disease. By applying T-lymphocytes, the treatment aims to enhance the body's immune response and fight against certain diseases.","oneSentence":"Application of T-lymphocytes targets the immune system","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:28:49.377Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of various cancers"}]},"trialDetails":[{"nctId":"NCT06985498","phase":"PHASE2","title":"Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-06-01","conditions":"Acute Lymphobkastic Leukemia","enrollment":40},{"nctId":"NCT07476729","phase":"PHASE3","title":"International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)","status":"NOT_YET_RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2026-04-01","conditions":"B-Cell Acute Lymphoblastic Leukaemia","enrollment":750},{"nctId":"NCT06047379","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","status":"RECRUITING","sponsor":"Neonc Technologies, Inc.","startDate":"2023-11-01","conditions":"Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult","enrollment":134},{"nctId":"NCT07437534","phase":"PHASE4","title":"Comparative Evaluation of the Safety and Effectiveness of Crisaborole Ointment (2%) Versus Tacrolimus Ointment (0.1%) for the Topical Treatment of Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"Hayat Abad Medical Complex, Peshawar","startDate":"2026-03-01","conditions":"Atopic Dermatitis","enrollment":148},{"nctId":"NCT06990087","phase":"PHASE2","title":"T-cell Therapy in Patients With PML","status":"RECRUITING","sponsor":"Hannover Medical School","startDate":"2026-02-06","conditions":"Progressive Multifocal Leucoencephalopathy (PML)","enrollment":23},{"nctId":"NCT06789198","phase":"PHASE1","title":"Peptide Vaccine for Fibrolamellar Hepatocellular Carcinoma Patients and Other Tumor Entities Carrying the Driver Fusion DNAJB1-PRKACA","status":"RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2025-07-08","conditions":"Fibrolamellar Hepatocellular Carcinoma (FLC)","enrollment":20},{"nctId":"NCT07234721","phase":"EARLY_PHASE1","title":"SL4903 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-02-01","conditions":"Relapsed and Refractory Multiple Myeloma (RRMM)","enrollment":9},{"nctId":"NCT05872854","phase":"PHASE2","title":"Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light","status":"COMPLETED","sponsor":"Ellen Kim, MD","startDate":"2023-08-21","conditions":"Cutaneous T Cell Lymphoma, Mycosis Fungoides","enrollment":10},{"nctId":"NCT00893035","phase":"","title":"Evaluation of an Apoptotic Test for Predicting Late Toxicities After Radiotherapy in Breast and Prostate Cancer Patients","status":"COMPLETED","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2006-06","conditions":"Breast Cancer, Prostate Cancer","enrollment":885},{"nctId":"NCT04691622","phase":"PHASE1","title":"Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts","status":"RECRUITING","sponsor":"Children's National Research Institute","startDate":"2022-03-17","conditions":"Viral Infection, Hematopoietic Stem Cell Transplantation (HSCT), Primary Immunodeficiency Disorders (PID)","enrollment":48},{"nctId":"NCT07138547","phase":"PHASE1, PHASE2","title":"GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-12-26","conditions":"Lymphoma","enrollment":40},{"nctId":"NCT07285434","phase":"EARLY_PHASE1","title":"Clinical Study of the Therapeutic Effectiveness of In-silico-Designed, Machine Learning Inspired, and Quantum-molecularly Coupled Personalized Neoantigenic Vaccines Microlyvaq™ in Patients With Advanced Non-small Cell Lung Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Biogenea Pharmaceuticals Ltd.","startDate":"2026-02-02","conditions":"NSCLC (Non-small Cell Lung Cancer), Squamous Lung Cancer With FGFR1 Amplification, Non-Squamous Non Small Cell Lung Cancer","enrollment":90},{"nctId":"NCT06698822","phase":"PHASE2","title":"A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-03-10","conditions":"Cutaneous T-Cell Lymphoma","enrollment":20},{"nctId":"NCT03300492","phase":"PHASE1, PHASE2","title":"Expanded Natural Killer Cells Following Haploidentical HSCT for AML/MDS","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2018-11-12","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":10},{"nctId":"NCT02812290","phase":"","title":"Diagnostic and Therapeutic Applications of Microarrays in Lung Transplantation","status":"RECRUITING","sponsor":"University of Alberta","startDate":"2016-05","conditions":"Lung Transplant Rejection","enrollment":700},{"nctId":"NCT06470451","phase":"PHASE3","title":"Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL","status":"RECRUITING","sponsor":"Soligenix","startDate":"2025-01-07","conditions":"CTCL/ Mycosis Fungoides, CTCL, Mycosis Fungoides","enrollment":80},{"nctId":"NCT05185258","phase":"PHASE4","title":"Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2022-02-16","conditions":"Psoriasis Vulgaris, Psoriasis, Skin Diseases","enrollment":12},{"nctId":"NCT04808245","phase":"PHASE1","title":"A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"German Cancer Research Center","startDate":"2023-02-15","conditions":"Newly Diagnosed H3-mutated Glioma","enrollment":15},{"nctId":"NCT06912529","phase":"PHASE2","title":"Axicabtagene Ciloleucel CAR T-cells in Patients With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma","status":"TERMINATED","sponsor":"Universität Münster","startDate":"2025-03-13","conditions":"B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent","enrollment":1},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT07047573","phase":"","title":"Multi-omics Detection Techniques for Differentiating Benign and Malignant Pulmonary Nodules","status":"RECRUITING","sponsor":"Zhao Jun","startDate":"2025-06-01","conditions":"Lung Cancer (Diagnosis), Pulmonary Nodule Persistent","enrollment":150},{"nctId":"NCT05106192","phase":"NA","title":"Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System.","status":"WITHDRAWN","sponsor":"Case Comprehensive Cancer Center","startDate":"2022-04-01","conditions":"Mycosis Fungoides of Skin (Diagnosis), Cutaneous T-cell Lymphoma, Non Hodgkin Lymphoma","enrollment":""},{"nctId":"NCT03984968","phase":"PHASE1, PHASE2","title":"CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2017-07-10","conditions":"Acute Lymphoblastic Leukemia, Adult B-Cell","enrollment":34},{"nctId":"NCT05908643","phase":"PHASE1, PHASE2","title":"A First-In-Human Trial of pTTL in Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Neogap Therapeutics AB","startDate":"2023-03-15","conditions":"Colorectal Cancer","enrollment":16},{"nctId":"NCT06390059","phase":"PHASE2","title":"EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"NovoCure Ltd.","startDate":"2023-08-28","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma","enrollment":84},{"nctId":"NCT06911710","phase":"PHASE1, PHASE2","title":"The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors","status":"RECRUITING","sponsor":"Tianjin Medical University General Hospital","startDate":"2024-11-09","conditions":"Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL), AML (Acute Myelogenous Leukemia), Myeloma Multiple","enrollment":90},{"nctId":"NCT02007356","phase":"PHASE2","title":"A Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipients of Hematopoietic Stem Cell Transplantation With Post-transplant Viral Infections Using the Cytokine Capture System®","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2014-12","conditions":"Adenovirus Infection, EBV, Cytomegalovirus Infections","enrollment":30},{"nctId":"NCT06823323","phase":"NA","title":"The Study on the Efficacy and Safety of Lactobacillus Johnsonii in Combination with CapeOX and Pembrolizumab for the Treatment of MSS/pMMR Metastatic Colorectal Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-03-01","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":150},{"nctId":"NCT04883645","phase":"EARLY_PHASE1","title":"Neoadjuvant Imiquimod Immunotherapy for Oral Cancer","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2022-04-28","conditions":"Oral Squamous Cell Carcinoma","enrollment":16},{"nctId":"NCT05937295","phase":"PHASE1","title":"FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined with Immune Checkpoint Inhibition","status":"RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2023-09-26","conditions":"Fibrolamellar Hepatocellular Carcinoma","enrollment":20},{"nctId":"NCT06441955","phase":"PHASE4","title":"Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.","status":"RECRUITING","sponsor":"Well- Konnect Healthcare Services and Research Firm","startDate":"2024-03-01","conditions":"COVID-19, Long Haul","enrollment":100},{"nctId":"NCT06705725","phase":"PHASE1","title":"Phase I Clinical Study of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Carbiogene Therapeutics Co. Ltd.","startDate":"2024-12-26","conditions":"Multiple Myeloma","enrollment":38},{"nctId":"NCT06665295","phase":"NA","title":"THRIVE-CAR-T Digital App","status":"NOT_YET_RECRUITING","sponsor":"Patrick C. Johnson, MD","startDate":"2024-11-01","conditions":"CAR T-Cell Therapy","enrollment":100},{"nctId":"NCT04011033","phase":"PHASE2","title":"Study of Adoptive Transfer of iNKT Cells Combined With TAE/TACE to Treat Unresectable HCC","status":"COMPLETED","sponsor":"Beijing YouAn Hospital","startDate":"2018-03-01","conditions":"Hepatocellular Carcinoma","enrollment":60},{"nctId":"NCT06593145","phase":"PHASE1","title":"CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms","status":"RECRUITING","sponsor":"FamiCordTx","startDate":"2023-05-24","conditions":"Acute Lymphoblastic Leukemia (ALL), Mantle Cell Lymphoma (MCL), Large B-cell Lymphoma","enrollment":6},{"nctId":"NCT03879512","phase":"PHASE1, PHASE2","title":"Autologous Dendritic Cells, Metronomic Cyclophosphamide and Checkpoint Blockade in Children With Relapsed HGG","status":"COMPLETED","sponsor":"Wuerzburg University Hospital","startDate":"2018-02-07","conditions":"Childhood Glioblastoma","enrollment":24},{"nctId":"NCT06585124","phase":"","title":"Flow Cytometry for the Study of T-Cell Populations in Hemophagocytic Lymphohistiocytosis Associated With Lymphomas","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2024-05-01","conditions":"Lymphoma, Hemophagocytic Lymphohistiocytoses","enrollment":150},{"nctId":"NCT02192021","phase":"PHASE1","title":"Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL)","status":"COMPLETED","sponsor":"Falo, Louis, MD","startDate":"2016-03-09","conditions":"Cutaneous T Cell Lymphoma","enrollment":20},{"nctId":"NCT06482684","phase":"PHASE2","title":"CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma","status":"RECRUITING","sponsor":"Christian Schmidt, MD","startDate":"2024-02-15","conditions":"Mantle Cell Lymphoma","enrollment":150},{"nctId":"NCT05064787","phase":"NA","title":"Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy","status":"COMPLETED","sponsor":"Pack Health","startDate":"2022-03-11","conditions":"Lymphoma, Lymphoma, B-Cell, Leukemia","enrollment":45},{"nctId":"NCT05982275","phase":"PHASE1, PHASE2","title":"Trial of an Investigational Drug After Rejecting the Relapse of an Allogeneic Transplant","status":"NOT_YET_RECRUITING","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2024-12-30","conditions":"Multiple Myeloma, Allogeneic Stem Cell Transplantation","enrollment":25},{"nctId":"NCT05579275","phase":"EARLY_PHASE1","title":"Evaluate the Safety and Tolerability of JCXH-212 Monotherapy and Combined With Toripalimab in the Treatment of Malignant Solid Tumors","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2023-02-06","conditions":"Malignant Solid Tumors","enrollment":24},{"nctId":"NCT06376721","phase":"PHASE1, PHASE2","title":"Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma","status":"RECRUITING","sponsor":"Beijing Tongren Hospital","startDate":"2024-04-14","conditions":"Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, T-lymphoblastic Lymphoma","enrollment":43},{"nctId":"NCT05354973","phase":"","title":"ePRO for the Timely Detection of Side Effects in Cancer Patients Undergoing CAR T Immunotherapy","status":"RECRUITING","sponsor":"Stiftung Swiss Tumor Institute","startDate":"2022-03-21","conditions":"Patient Reported Outcome Measures, CAR T-Cell Therapy","enrollment":11},{"nctId":"NCT06238336","phase":"PHASE2, PHASE3","title":"Clinical Study of CAR-T Technology for the Treatment of Relapsed Refractory Malignant Haematological Tumours","status":"UNKNOWN","sponsor":"Shanxi Bethune Hospital","startDate":"2020-06-15","conditions":"Hematological Malignancy","enrollment":30},{"nctId":"NCT04218825","phase":"PHASE2","title":"REACH: Study to Determine the Aetiology of Chlormethine Gel Induced-skin Drug Reaction in Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL)","status":"TERMINATED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2022-03-29","conditions":"Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL) (Stage IA-IB)","enrollment":2},{"nctId":"NCT06125652","phase":"PHASE1, PHASE2","title":"Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)","status":"RECRUITING","sponsor":"Xuzhou Medical University","startDate":"2023-11-04","conditions":"Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse","enrollment":20},{"nctId":"NCT03927573","phase":"PHASE1","title":"Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker","status":"TERMINATED","sponsor":"AvenCell Europe GmbH","startDate":"2019-04-15","conditions":"Non-small Cell Lung Cancer, Prostate Cancer, Renal Cancer","enrollment":23},{"nctId":"NCT05380635","phase":"PHASE2","title":"PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma","status":"COMPLETED","sponsor":"Soligenix","startDate":"2022-05-09","conditions":"Cutaneous T-Cell Lymphoma/Mycosis Fungoides","enrollment":9},{"nctId":"NCT05199961","phase":"NA","title":"Quality of Life of Adults With Diffuse Large B-cell Lymphoma Treated With Tisagenlecleucel","status":"TERMINATED","sponsor":"Pack Health","startDate":"2022-01-25","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":4},{"nctId":"NCT05812326","phase":"PHASE1, PHASE2","title":"PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer","status":"COMPLETED","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2019-05-17","conditions":"Advanced Breast Cancer, Breast Neoplasm Malignant Female","enrollment":15},{"nctId":"NCT01040026","phase":"PHASE1, PHASE2","title":"Expanded Natural Killer (NK) Cells for Multiple Myeloma Study","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2012-10","conditions":"Multiple Myeloma","enrollment":10},{"nctId":"NCT05737589","phase":"","title":"Circulating Tumor DNA and T Cell Repertoire Predict Radiotherapeutic Outcomes in NSCLC Patients With Brain Metastasis","status":"UNKNOWN","sponsor":"Xiaorong Dong","startDate":"2023-02-13","conditions":"Carcinoma, Non-Small-Cell Lung, Brain Metastases","enrollment":50},{"nctId":"NCT05362331","phase":"NA","title":"Companion for CAR-T Web App During Chimeric Antigen Receptor T-cell Therapy","status":"WITHDRAWN","sponsor":"University of California, San Francisco","startDate":"2023-01-01","conditions":"Lymphoma, Leukemia, Plasma Cell Dyscrasia","enrollment":""},{"nctId":"NCT04030195","phase":"PHASE1, PHASE2","title":"Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL","status":"COMPLETED","sponsor":"Precision BioSciences, Inc.","startDate":"2020-03-24","conditions":"Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse, Non-Hodgkin's Lymphoma Refractory","enrollment":18},{"nctId":"NCT02802943","phase":"PHASE2","title":"iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL","status":"COMPLETED","sponsor":"University Hospital Tuebingen","startDate":"2016-10-05","conditions":"Leukemia, Chronic Lymphatic","enrollment":56},{"nctId":"NCT03516760","phase":"PHASE1","title":"Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"AvenCell Europe GmbH","startDate":"2018-04-11","conditions":"Acute Myeloid Leukemia, Relapsed AML, Refractory AML","enrollment":36},{"nctId":"NCT05488132","phase":"PHASE1, PHASE2","title":"Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)","status":"UNKNOWN","sponsor":"Xuzhou Medical University","startDate":"2022-04-01","conditions":"Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse","enrollment":20},{"nctId":"NCT02758223","phase":"PHASE1, PHASE2","title":"Prophylactic Application of Donor-derived TCM After Allogeneic HSCT","status":"COMPLETED","sponsor":"Wuerzburg University Hospital","startDate":"2016-04","conditions":"Leukemia, Myeloid, Acute, Myelodysplastic Syndromes","enrollment":16},{"nctId":"NCT04844086","phase":"PHASE1","title":"RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies","status":"TERMINATED","sponsor":"Eden BioCell Ltd.","startDate":"2021-03-02","conditions":"B-cell Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory","enrollment":2},{"nctId":"NCT05141253","phase":"EARLY_PHASE1","title":"Safety and Efficacy of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2022-01-12","conditions":"Cancer","enrollment":24},{"nctId":"NCT02448381","phase":"PHASE3","title":"FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)","status":"COMPLETED","sponsor":"Soligenix","startDate":"2015-12","conditions":"Cutaneous T-Cell Lymphoma","enrollment":169},{"nctId":"NCT04313231","phase":"","title":"Sterile Inflammation and Molecular Aberrations in MDS","status":"UNKNOWN","sponsor":"Medical University Innsbruck","startDate":"2020-01-22","conditions":"Myelodysplastic Syndromes","enrollment":130},{"nctId":"NCT05166070","phase":"EARLY_PHASE1","title":"An Exploratory Clinical Study of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-01-01","conditions":"Solid Tumor","enrollment":24},{"nctId":"NCT03380026","phase":"PHASE2","title":"Mechlorethamine Induced Contact Dermatitis Avoidance Study","status":"COMPLETED","sponsor":"Rochester Skin Lymphoma Medical Group, PLLC","startDate":"2017-12-13","conditions":"Cutaneous T-cell Lymphoma, Cutaneous T-cell Lymphoma Stage I, Mycosis Fungoides","enrollment":28},{"nctId":"NCT04312490","phase":"NA","title":"Presentation, Patterns of Myocardial Damage, and Clinical Course of Viral Myocarditis","status":"COMPLETED","sponsor":"Assiut University","startDate":"2019-09-16","conditions":"Myocarditis Viral","enrollment":51},{"nctId":"NCT05117138","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors","status":"UNKNOWN","sponsor":"Beijing Immunochina Medical Science & Technology Co., Ltd.","startDate":"2022-01-01","conditions":"Melanoma, Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma","enrollment":39},{"nctId":"NCT05054465","phase":"PHASE1, PHASE2","title":"A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL","status":"NOT_YET_RECRUITING","sponsor":"Israeli Medical Association","startDate":"2021-10-01","conditions":"Acute Lymphoblastic Leukemia","enrollment":48},{"nctId":"NCT00960752","phase":"PHASE2","title":"Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-05-20","conditions":"Melanoma","enrollment":47},{"nctId":"NCT02301494","phase":"NA","title":"Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma","status":"WITHDRAWN","sponsor":"Rochester General Hospital","startDate":"2020-04","conditions":"Mycosis Fungoides","enrollment":""},{"nctId":"NCT03292406","phase":"PHASE2","title":"A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2017-12-19","conditions":"Cutaneous T Cell Lymphoma","enrollment":86},{"nctId":"NCT04702841","phase":"EARLY_PHASE1","title":"CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors","status":"UNKNOWN","sponsor":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","startDate":"2020-06-03","conditions":"CAR, Malignant Tumors","enrollment":8},{"nctId":"NCT04003168","phase":"PHASE1","title":"Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma","status":"UNKNOWN","sponsor":"Hrain Biotechnology Co., Ltd.","startDate":"2019-07-01","conditions":"Multiple Myeloma","enrollment":18},{"nctId":"NCT04723121","phase":"NA","title":"Can We Predict of the Response of High Risk Non Muscle Invasive Bladder Cancer Patients to Intravesical Bacillus Calmette-Guerin? The Role of Immunological Markers","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2013-03-01","conditions":"Bladder Cancer","enrollment":204},{"nctId":"NCT04702503","phase":"PHASE1","title":"Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL)","status":"COMPLETED","sponsor":"Moleculin Biotech, Inc.","startDate":"2019-03-08","conditions":"Cutaneous T-Cell Lymphoma/Mycosis Fungoides","enrollment":5},{"nctId":"NCT03380039","phase":"NA","title":"Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma","status":"UNKNOWN","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2017-10-13","conditions":"Refractory or Relapsed Multiple Myeloma","enrollment":6},{"nctId":"NCT03302403","phase":"NA","title":"Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors","status":"UNKNOWN","sponsor":"Kang YU","startDate":"2017-12-29","conditions":"B Cell Lymphoma, B Cell Leukemia, Myeloma","enrollment":18},{"nctId":"NCT03716856","phase":"PHASE1","title":"Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2018-03-23","conditions":"Refractory or Relapsed Multiple Myeloma","enrollment":11},{"nctId":"NCT04004637","phase":"PHASE1","title":"CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia","status":"UNKNOWN","sponsor":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","startDate":"2019-08-25","conditions":"T-lymphoblastic Lymphoma, NK/T Cell Lymphoma, Acute Lymphocytic Leukemia","enrollment":10},{"nctId":"NCT04389385","phase":"PHASE1","title":"COVID-19 Specific T Cell Derived Exosomes (CSTC-Exo)","status":"UNKNOWN","sponsor":"TC Erciyes University","startDate":"2020-05-01","conditions":"Corona Virus Infection, Pneumonia","enrollment":60},{"nctId":"NCT03983460","phase":"NA","title":"Dupilumab Impact on Skin Resident Memory T Cells","status":"UNKNOWN","sponsor":"Association pour la Recherche Clinique et Immunologique","startDate":"2020-03-09","conditions":"Atopic Dermatitis","enrollment":20},{"nctId":"NCT01473940","phase":"PHASE1","title":"Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2012-06-11","conditions":"Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer","enrollment":21},{"nctId":"NCT01742793","phase":"PHASE1","title":"An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)","status":"TERMINATED","sponsor":"Yale University","startDate":"2012-10","conditions":"Hodgkin's Lymphoma, Mature T-cell Lymphoma, Multiple Myeloma","enrollment":12},{"nctId":"NCT03069599","phase":"","title":"Immune Response After Pancreatic Cancer Treatment","status":"TERMINATED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2017-02-15","conditions":"Pancreatic Cancer","enrollment":38},{"nctId":"NCT04237428","phase":"NA","title":"CD19-CART in the Treatment of R/R CD19 Positive Non-Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","startDate":"2019-05-31","conditions":"Non Hodgkin Lymphoma","enrollment":20},{"nctId":"NCT03159585","phase":"PHASE1","title":"To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors","status":"COMPLETED","sponsor":"Zhujiang Hospital","startDate":"2017-04-14","conditions":"Liver Cancer Stage IV, Gastric Cancer Stage IV, Esophageal Cancer, Stage IV","enrollment":6},{"nctId":"NCT00785330","phase":"PHASE2","title":"Allo-hNHL (FluBuCy)","status":"COMPLETED","sponsor":"Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH","startDate":"2004-04","conditions":"Non-Hodgkin's Lymphoma","enrollment":84},{"nctId":"NCT04184414","phase":"EARLY_PHASE1","title":"The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies","status":"UNKNOWN","sponsor":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","startDate":"2018-01-09","conditions":"B Acute Lymphoblastic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma","enrollment":10},{"nctId":"NCT03146234","phase":"NA","title":"CAR-GPC3 T Cells in Patients With Refractory Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"RenJi Hospital","startDate":"2017-03-17","conditions":"Hepatocellular Carcinoma","enrollment":7},{"nctId":"NCT01676831","phase":"PHASE1, PHASE2","title":"Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL)","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2012-02","conditions":"Cutaneous T Cell Lymphoma","enrollment":13},{"nctId":"NCT02842138","phase":"PHASE1","title":"Autologous CD19 CAR T Cells in Relapsed or Refractory B-cell Lymphoma","status":"UNKNOWN","sponsor":"Peking University","startDate":"2016-06","conditions":"B-cell Lymphoma","enrollment":25},{"nctId":"NCT01007526","phase":"PHASE2","title":"Concomitant Chemo-radiotherapy Plus VIDL Chemotherapy in NK/T-cell Lymphoma","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2008-04","conditions":"NK/T-cell Lymphoma of Nasal Cavity","enrollment":31},{"nctId":"NCT02421900","phase":"","title":"Analysis of the Role of T-cell Response in Patients With Atrial Fibrillation for Clinical Application","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2015-04-01","conditions":"Atrial Fibrillation","enrollment":100},{"nctId":"NCT00961220","phase":"PHASE1, PHASE2","title":"O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-02-01","conditions":"Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage I Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7","enrollment":17},{"nctId":"NCT03159819","phase":"NA","title":"Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma","status":"UNKNOWN","sponsor":"Changhai Hospital","startDate":"2017-04-01","conditions":"Advanced Gastric Adenocarcinoma, Pancreatic Adenocarcinoma","enrollment":24},{"nctId":"NCT01187446","phase":"PHASE1, PHASE2","title":"Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides","status":"TERMINATED","sponsor":"Stanford University","startDate":"2010-12","conditions":"Cutaneous Lymphoma, Cutaneous T-cell Lymphoma","enrollment":28},{"nctId":"NCT02980315","phase":"PHASE1, PHASE2","title":"A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application","status":"UNKNOWN","sponsor":"The Second Hospital of Nanjing Medical University","startDate":"2016-11","conditions":"Nasopharyngeal Neoplasms","enrollment":20},{"nctId":"NCT00470392","phase":"NA","title":"Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2007-05","conditions":"Psoriasis","enrollment":9},{"nctId":"NCT02794961","phase":"PHASE1, PHASE2","title":"CD22 Targeting CAR-T Therapy Against B Cell Hematological Malignancies","status":"UNKNOWN","sponsor":"Kai Lin Xu; Jun Nian Zheng","startDate":"2016-06","conditions":"Recurrent or Refractory B Cell Malignancy","enrollment":10},{"nctId":"NCT01804335","phase":"PHASE1","title":"CD5789 in Early Cutaneous T-Cell Lymphoma (CTCL)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-02","conditions":"Lymphoma","enrollment":11}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Application of T-lymphocytes","genericName":"Application of T-lymphocytes","companyName":"Hannover Medical School","companyId":"hannover-medical-school","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Application of T-lymphocytes targets the immune system Used for Treatment of various cancers.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}